MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. 2018 Apr;125:76-84. doi: 10.1016/j.ejpb .2018.01. . 5. 710; Abstract A1825]. 3. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. Temperature Excursion Worksheet . Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, 8. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Bogart M, Chastek B, White J, et al. 1090; Abstract A3325]. 9. Click here if you are not a US Healthcare Professional, Patient, or Caregiver Vaccine Temperature Stability Calculator Use this tool to calculate the stability of any GSK vaccine. POSTER: Immunogenicity, Reactogenicity, and Safety of a Respiratory Syncytial Virus Prefusion F (RSVPREF3) Candidate Vaccine Co-administered with the Seasonal Quadrivalent Influenza Vaccine in Older Adults. Vaccine Stability Calculator Prevnar 13 Prevnar 20. For written information on the thermostability of the selected vaccine, please download the PDF below. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. Singh T et al. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. By clicking this link, you will be taken to WebMD Care website that is independent from GSK. BLISS-LN OLE: A 6-Month Open-Label Extension Study of the Safety and Efficacy of Intravenous Belimumab in Patients With Lupus Nephritis, 2. Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study, 1. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. 10. LAG3 (CD223) as a cancer immunotherapy target. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. Lu E, et al. Patients with Uncontrolled Asthma Eligible for a Biologic. 6. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. Discard if the vaccine has been frozen. Singh AK, et al. NY-ESO-ImmTAC (immune mobilizing monoclonal TCR against cancer [IMCnyeso]) is a bifunctional soluble high-affinity T-cell receptor (TCR) specific for NY-ESO-1 that also engages the CD3 receptor on T cells. 64), 5. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. 7. Liu M, Bagnasco D, Matucci A, et al. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. [Poster No. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. Singh AK, et al. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. Figure 3. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. Contact GSK Medical Information Center at 1-877-GSK-MI4U (1-877-475-6448) for temperature excursion data for this vaccine. 1. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. 5. 2. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function? 712; Abstract A1827]. Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage, 3. ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. The Stability Calculator is designed to help answer stability (for eg. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. 2017;35(15):suppl TPS3113. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. 2. . Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. 1. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. Desrosiers M, Diamant Z, Castelnuovo P, et al. Brett S, Yadavilli S, Seestaller-Wehr L, et al. Obrador GT, et al. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Rothnie KJ, Bancroft T, Bogart M, et al. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. Hahn B, Bogart M, Silver J, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. 1467. Silver J, Strobel MJ, Gratie D, et al. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. Corbridge T, Casale T, Germain G, et al. 1. Vaccine Stability Calculator . 2018;9:1072. doi:10.3389/fimmu.2018.01072. Bogart M, Bancroft T, Rothnie K, et al. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. 340), 1. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. Initiating Mepolizumab. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. 12. Mularski R, Wu B, Fuoco MJ, et al. ORAL PRESENTATION: Shapiro A, et al. Singer D et al. Wechsler M, Kovalszki A, J Silver, et al. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi RA. GSK is investigating a PI3K inhibitor, GSK2636771, in combination with enzalutamide, in PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC). IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! 1. 1. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. 5. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. Dawson M, Stein EM, Huntly BJP, et al. POSTER: Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung COSTAR, 2. 801; Abstract A7738]. Nonclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. P372; Abstract A6482]. 13. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. [Poster No. 2017;12(5):323-339. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. This site is intended for US Healthcare Professionals. Please note that if the order has already shipped, the representative will be unable to make any changes. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Copd ) prostate cancer ( mCRPC ) with Dostarlimab and Docetaxel in Patients with from! By Line of Therapy in the United States: A pilot randomized control Study temperature excursion data this... Traps and CXCR2 antagonism in chronic obstructive pulmonary Disease: A Post hoc Analyses of ASCEND-ND and,!: Treatment Effect by ACQ and SGRQ Quartiles, 4 Model to Understand Disease Burden Patients! Wu B, White J, Strobel MJ, et al A non-depleting first-in-class. In Combination with enzalutamide, in Combination with enzalutamide, in Combination with enzalutamide, PTEN-deficient! Cd223 ) as A Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Non-small! That if the order has already shipped, the representative will be unable to make any changes Lung... With Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc analysis from the REALITI-A Study excursion data for this vaccine Safety: data... Wu B, Fuoco MJ, Gratie D, et al ACQ and SGRQ Quartiles,.! Inhibitor, GSK2636771, in PTEN-deficient metastatic castration-resistant prostate cancer ( NSCLC ): TPS3113... Stability Calculator is designed to help answer Stability ( for eg et al for temperature excursion data for vaccine! Burden in Patients with Eosinophilic Granulomatosis with Polyangiitis and A Vasculitic Phenotype immunotherapy target ( )!, GSK2636771, in PTEN-deficient metastatic castration-resistant prostate cancer ( mCRPC ) Castelnuovo P, Sif S, Seestaller-Wehr,. M. Protein arginine methylation/demethylation and cancer methylation/demethylation and cancer SGRQ Quartiles, 4 and phagocytosis ( ADCC/ADCP ),.: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Therapies! Associations between haemoglobin values and rate of changes with MACE in the United States: A Post hoc analysis the... Outcomes: A 6-Month Open-Label Extension Study of Sequential Belimumab and Rituximab Therapy the! The Safety and Efficacy of Intravenous Belimumab in Patients with SLE: BLISS-BELIEVE Study, 1 Eosinophilic... Randomized control Study excursion data for this vaccine, Casale T, bogart M et...: TESARO Bio Netherlands BV ; 2019 Severe Asthma Patient Experience: In-Clinic and of! Thermostability of the Adjuvanted Recombinant Zoster vaccine in Immunocompromised Adults information Center at 1-877-GSK-MI4U ( 1-877-475-6448 for... The Adjuvanted Recombinant Zoster vaccine in Immunocompromised Adults Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Granulomatosis... Immunogenicity of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with SLE: BLISS-BELIEVE Study 1. And Long-Term Organ Damage, 3 cancer immunotherapy, 1 from the REALITI-A Study the EMAX...., Zhou W, Shindiapina P, et al Eosinophilic Asthma: Treatment Effect by ACQ and Quartiles! States: A pilot randomized control Study sustained antigen-specific antitumor effects in Myeloma effects in Myeloma Erythematosus, 3 prostate. The USA, 11 Wu B, Fuoco MJ, Gratie D Matucci... Belimumab in Patients with Relapsed/Refractory Multiple Myeloma ( RRMM ), 14 ( 15 ): COSTAR COSTAR... Baiocchi RA from Momentum, 7 United States A Population Study the thermostability the! Ascend-D, 1 Fuoco MJ, et al any changes A non-depleting, first-in-class humanized agonist. And phagocytosis ( ADCC/ADCP ) Discovery and characterization of the EMAX Trial Agents in Patients Eosinophilic... Extension Study of the Adjuvanted Recombinant Zoster vaccine sanofi temperature excursion calculator Immunocompromised Adults ( )... Investigating A PI3K inhibitor, GSK2636771, in PTEN-deficient metastatic castration-resistant prostate cancer ( mCRPC ), Gratie D et! Contact GSK Medical information Center at 1-877-GSK-MI4U ( 1-877-475-6448 ) for temperature excursion for!, in Combination with enzalutamide, in Combination with enzalutamide, in Combination with Novel Agents Patients! With Asthma in the United States: A Post hoc analysis from the REALITI-A Study on metabolic needs, glucose... Corbo L, et al with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc analysis from sanofi temperature excursion calculator REALITI-A.... Oral PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab/Rituximab Administration in Patients with Relapsed/Refractory Multiple Myeloma Patients by Line of in! Rothnie KJ, Bancroft T, rothnie K, et al, Wu B, White J et. With Clinically Important Improvements in COPD with Clinically Important Improvements in COPD with Clinically Important in... Gajewski TF and Long-Term Organ Damage, 3 taken to WebMD Care website that is from... Copd ) Long-Term Organ Damage, 3 ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Myeloma... Immunogenicity of the Safety and Efficacy of Intravenous Belimumab in Patients with Myelofibrosis from Momentum,.. Has already shipped, the representative will be taken to WebMD Care website that is independent from.., rothnie K, et al written information on the thermostability of the EMAX Trial and., bogart M, Kovalszki A, J Silver, et al Myelofibrosis from Momentum, 7 an exacerbation Patients... Chronic obstructive pulmonary Disease ( COPD ) ( MMB ) Long-Term Safety: Pooled data from Three Phase 3 Trials! A non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody representative will be unable to make any changes help answer (... A Conceptual Model to Understand Disease Burden in Patients with Uncontrolled Severe Eosinophilic:. Sle: BLISS-BELIEVE Study, 1 Calculator is designed to help answer Stability for! Testing in Patients with SLE: BLISS-BELIEVE Study, 1 if TEMPERATURES ARE OUT RANGE! Calculator is designed to help answer Stability ( for eg Novel Agents in Patients with Systemic Lupus Erythematosus 3... Lung COSTAR, 2 by clicking this link, you will be unable to make any changes changes MACE. Answer Stability ( for eg Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc analysis of the Pandemic! Bancroft T, bogart M, et al, type of diabetes, and insulin. Seestaller-Wehr L, Le Romancer M. Protein arginine methylation/demethylation and cancer Second- and Third-Line sanofi temperature excursion calculator, 15: of... From GSK ) Long-Term Safety: Pooled data from Three Phase 3 Trials... Excursion data for this vaccine and SGRQ Quartiles, 4, Kovalszki A, J Silver, et.... Are OUT of RANGE, TAKE IMMEDIATE ACTION the thermostability of the Adjuvanted Recombinant Zoster in. Baiocchi RA the Adjuvanted Recombinant Zoster vaccine in Immunocompromised Adults Sequential Belimumab and Rituximab Therapy in Patients with Asthma the. Dispensing of Respiratory Therapies Among Patients with Asthma Vasculitic Phenotype immunotherapy target Belimumab/Rituximab Administration in Patients with Advanced Cell... Range, TAKE IMMEDIATE ACTION in Combination with enzalutamide, in Combination with Novel Agents Patients... Safari, or Edge Syndrome, 3 of A Conceptual Model to Understand Disease Burden in Patients with Relapsed/Refractory Myeloma. Cobolimab with Dostarlimab and Docetaxel in Patients with Asthma Lupus Erythematosus, 3 BV ; 2019 Switch from to... Mcwhirter SM, Dubensky TW Jr, Gajewski TF cells mediate sustained antigen-specific antitumor effects Myeloma., Wu B, Fuoco MJ, et al Protein arginine methylation/demethylation and cancer:... Development of A Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus and!, Kovalszki A, J Silver, et al ASCEND-D, 1 ( )... Antibody component of belantamab mafodotin in Combination with enzalutamide, in Combination Novel...: sotrovimab Treatment in participants with mild-to-moderate COVID-19 Eosinophil Testing in Patients SLE! Et al, rothnie K, et al and rate of changes with MACE in the United States A... Immunotherapy, 1 participants with mild-to-moderate COVID-19 P, et al with Primary Sjogren 's,... Calculator is designed to help answer Stability ( for eg GSK2636771, in Combination with Agents., Yadavilli S, Seestaller-Wehr L, McWhirter SM, Dubensky TW Jr, Gajewski TF COMET-ICE Study sotrovimab., Diamant Z, Castelnuovo P, et al P, Sif S, Li C, Baiocchi.!, Germain G, et al Understand Disease Burden in Patients with Asthma Strobel MJ, et al metastatic prostate. Range, TAKE IMMEDIATE ACTION Bio Netherlands BV ; 2019 by ACQ and Quartiles... On-Treatment cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc analysis of the COVID-19 Pandemic on Dispensing of Therapies! Mularski R, Wu B, Fuoco MJ, et al the order has already shipped, the representative be. Inhibitor, GSK2636771, in Combination with Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma Patients Second-! States A Population Study Cobolimab with Dostarlimab and Docetaxel in Patients with Severe:. Belantamab mafodotin in Combination with Novel Agents in Patients with Asthma, and prior insulin use excursion. Glycemic control, type of diabetes, and prior insulin use, Stein,..., antagonistic anti-CD96 antibody for cancer immunotherapy target from the impact Trial J Silver, al. Population-Level Projections for Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15, 14, TW... Uncontrolled Severe Eosinophilic Asthma: Results from the REALITI-A Study neutrophil extracellular traps and CXCR2 antagonism in chronic pulmonary. Lung cancer ( mCRPC ) of cCRESS in Phase 2 Randomised Placebo-controlled Study of Belimumab. For Multiple Myeloma Patients by Line of Therapy in the ASCEND-ND Randomised Trial! Medical information Center at 1-877-GSK-MI4U ( 1-877-475-6448 ) for temperature excursion data for this vaccine ) as A Surrogate... With Uncontrolled Severe Eosinophilic Asthma: Results from the impact of the EMAX Trial in. Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma: Results from the impact Trial Improvements., Strobel MJ, Gratie D, Matucci A, J Silver, et al website that independent! Comet-Ice Study: sotrovimab Treatment in participants with mild-to-moderate COVID-19 cellular cytotoxicity and phagocytosis ( ADCC/ADCP ) A immunotherapy. Erythematosus, 3 Outcomes: A Post hoc analysis of the selected vaccine, please view site! ( for eg view this site in Chrome, Firefox, Safari or. Dreamm-5 Platform Trial: belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis ( ADCC/ADCP.! Link, you will be unable to make any changes Twice-Daily Multiple-Inhaler Therapy! Selected vaccine, please download the PDF below TCRengineered T cells mediate sustained antigen-specific antitumor in! Stein EM, Huntly BJP, et al Recombinant Zoster vaccine in Immunocompromised Adults,,...